EGF and nasopharyngeal carcinoma: Nevertheless, several clinical trials show that targeting the vascular endothelial growth factor (VEGF) signaling by bevacizumab, or targeting the epidermal growth factor (EGF) signaling by cetuximab, did not show clinical benefits in NPC patients, compared with conventional chemoradiotherapy (5–7).